New ideas on the origin of L-dopa-induced dyskinesias: Age, genes and neural plasticity

Trends in Pharmacological Sciences

Volumn 26, Issue 8, 2005, Pages 391-397

  Linazasoro, Gurutz ^a  

^a Centro de Investigacion Parkinson   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 [[2 [4 (4 FLUOROPHENYL)METHYL 1 PIPERIDINYL]ETHYL]SULFINYL] 2(3H) BENZOXAZOLONE; APOLIPOPROTEIN E; BENZOXAZOLE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CABERGOLINE; CATECHOL METHYLTRANSFERASE; CI 1041; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; IFENPRODIL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARKIN; PIPERIDINE DERIVATIVE; PROTEIN FOS; UNCLASSIFIED DRUG;

ALLELE; CHROMOSOME 1Q; CHROMOSOME 2P; CHROMOSOME 8Q; CLINICAL PROTOCOL; DENERVATION; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DYSKINESIA; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOPOGRAPHY; TREATMENT PLANNING;

EID: 22844435191     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.06.007     Document Type: Article

References (64)

1. J.A. Obeso Complications associated with chronic levodopa therapy in Parkinson's disease C.W. Olanow J.A. Obeso Beyond the Decade of the Brain Vol. 2 1997 Wells Medical Ltd 11 36
2. F. Calon Dopamine receptor stimulation: behavioural and biochemical consequences Trends Neurosci. 23 2000 S92 S100
3. T.H. Brown Learning and memory: basic mechanisms J.H. Byrne J.L. Roberts From Molecules to Networks. An Introduction to Cellular and Molecular Neuroscience 2004 Elsevier 499 574
4. C.R. Gerfen Molecular effects of dopamine on striatal projection pathways Trends Neurosci. 23 2000 S64 S70
5. P. Calabresi The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia Trends Neurosci. 19 1996 19 24
6. M.A. Cenci Transcription factors involved in the pathogenesis of levodopa-induced dyskinesia in a rat model of Parkinson's disease Amino Acids 23 2002 105 109
7. F. Calon Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416
8. J.Q. Wang Glutamate-regulated behaviour, transmitter release, gene expression and addictive plasticity in the striatum: roles of metabotropic glutamate receptors Current Pharmacology 1 2003 1 20
9. M.J. Kuhar Genes in drug abuse Drug Alcohol Depend. 62 2001 157 162
10. M. Andersson Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment Eur. J. Neurosci. 17 2003 661 666
11. B. Picconi Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia Nat. Neurosci. 6 2003 501 505
12. T.N. Chase Striatal plasticity and extrapyramidal motor dysfunction Parkinsonism Relat. Disord. 10 2004 305 313
13. N. Belanger Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys Mov. Disord. 18 2003 1436 1441
14. A. Hadj Tahar Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys Neurobiol. Dis. 15 2004 171 176
15. J.R. Sanes, and J.W. Litchman Can molecules explain long-term potentiation? Nat. Neurosci. 2 1999 597 604
16. C. Konradi Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia Neurobiol. Dis. 17 2004 219 236
17. A.M. Graybiel Network-level neuroplasticity in cortico-basal ganglia pathways Parkinsonism Relat. Disord. 10 2004 293 296
18. C.A. Barnes Long-term potentiation and the ageing brain Philos. Trans. R. Soc. Lond. B Biol. Sci. 358 2003 765 772
19. S.E. Leff Dopamine receptor turnover rates in rat striatum are age-dependent Proc. Natl. Acad. Sci. U. S. A. 81 1984 3910 3914
20. K. Nishi Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice Brain Res. 489 1989 157 162
21. T. Lu Gene regulation and DNA damage in the ageing human brain Nature 429 2004 883 891
22. P.R. Cox Mice lacking Tropomodulin-2 show enhanced long-term potentiation, hyperactivity, and deficits in learning and memory Mol. Cell. Neurosci. 23 2003 1 12
23. M.C.J. Dekker Parkinson's disease: piecing together a genetic jigsaw Brain 126 2003 1722 1733
24. C.M. Tanner Parkinson disease in twins: an etiologic study J. Am. Med. Assoc 281 1999 341 346
25. S. Karamohamed A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the Gene PD study Neurology 61 2003 1557 1561
26. Y.J. Li Age at onset in two common neurodegenerative diseases is genetically controlled Am. J. Hum. Genet. 70 2002 985 993
27. Y.J. Li Apolipoprotein E controls the risk and age of onset of Parkinson's disease Neurology 62 2004 2005 2009
28. N. Pankratz Genes influencing Parkinson disease onset. Replication of PARK3 and identification of novel loci Neurology 62 2004 1616 1618
29. C.J. Hong Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset Neurosci. Lett. 353 2003 75 77
30. Y. Momose Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms Ann. Neurol. 51 2002 133 136
31. A. Hakansson Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population Ann. Neurol. 53 2003 823
32. R.L. Oliveri Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD Neurology 53 1999 1425 1430
33. J. Wang Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD Neurology 56 2001 1757 1759
34. M. Zappia Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. An exploratory study Arch. Neurol. 62 2005 601 605
35. J. Wang Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease Neurosci. Lett. 308 2001 21 24
36. R. Kaiser L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism Neurology 60 2003 1750 1755
37. N. Turjanski PET studies on striatal dopaminergic receptor binding in drug naive and L-dopa treated Parkinson's disease patients with and without dyskinesia Neurology 49 1997 717 723
38. A. Kumar [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease Brain 126 2003 2648 2655
39. G. Linazasoro, and K.L. Leenders PET and motor complications in Parkinson's disease Brain 127 2004 E15
40. M. Watanabe Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease Neuropsychobiology 48 2003 190 193
41. H. Shimura Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet. 25 2000 302 305
42. J.M. George Characterization of a novel protein regulated during the critical period for song learning in the zebra fish Neuron 15 1995 361 372
43. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 2004 464 469
44. Y. Gilgun-Sherki Polymorphisms in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease Pharmacogenomics J. 4 2004 291 306
45. D.A. Greenberg Microarrays, markers of disease and the myth of "nonhypothesis-driven" research Ann. Neurol. 50 2001 695 696
46. F. Collins The case for a US prospective cohort study of genes and environment Nature 429 2004 475 477
47. D.W. Nebert Pharmacogenomics and "individualized drug therapy". High expectations and disappointing achievements Am. J. Pharmacogenomics 3 2003 361 370
48. V. Kostic Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease Neurology 41 1991 202 205
49. A. Schrag Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality Mov. Disord. 13 1998 885 894
50. P.J. Blanchet Risk factors for peak dose dyskinesia in 100 L-dopa treated parkinsonian patients Can. J. Neurol. Sci. 23 1996 189 193
51. D.A. Di Monte Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model Mov. Disord. 15 2000 459 466
52. R. De la Fuente Fernández Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model Brain 127 2004 888 899
53. G. Linazasoro Pharmacological and PET studies in patients with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications J. Neural Transm. 111 2004 497 509
54. D.M. Togasaki Levodopa induces dyskinesias in normal squirrel monkeys Ann. Neurol. 50 2001 254 257
55. N.L. Khan Parkin disease: a phenotypic study of a large case series Brain 126 2003 1279 1292
56. C. Scherfler Striatal and cortical pre and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism Brain 127 2004 1332 1342
57. N.L. Khan Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study Ann. Neurol. 52 2002 849 853
58. M. Dekker Clinical features and neuroimaging of PARK7-linked parkinsonism Mov. Disord. 18 2003 751 757
59. F. Calon Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications Mov. Disord. 18 2003 241 253
60. J.S. Schneider Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms Brain Res. 990 2003 38 44
61. M. Vidailhet Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology 44 1994 1613 1616
62. O. Rascol A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa New Engl. J. Med. 342 2000 1484 1491
63. A.J. Lees Ten-year follow-up of three different initial treatments in de-novo PD. A randomized trial Neurology 57 2001 1687 1694
64. The International HapMap Consortium The International HapMap Project Nature 426 2003 789 796